Tempest Therapeutics Inc
Change company Symbol lookup
Select an option...
TPST Tempest Therapeutics Inc
PETV PetVivo Holdings Inc
KMI Kinder Morgan Inc
NXPL NextPlat Corp
D Dominion Energy Inc
CVS CVS Health Corp
CVI CVR Energy Inc
CTRE CareTrust REIT Inc
CSWC Capital Southwest Corp
CSCO Cisco Systems Inc
Go

Health Care : Biotechnology |
Company profile

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Closing Price
$1.85
Day's Change
-0.20 (-9.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.04
Day's Low
1.76
Volume
(Heavy Day)
Volume:
142,808

10-day average volume:
64,949
142,808

Stocks are at Wall Street's year-end target. It's only early February.

5:09 pm ET February 2, 2023 (MarketWatch)
Print

By Joseph Adinolfi

Nasdaq Composite surges 16% to start 2023

Just like last year, Wall Street strategists look pretty wrong about their expectations for stock-market performance in 2023. But this time around, they're in the unusual position of having been too pessimistic.

Back in December, MarketWatch collected year-end price targets for the S&P 500 from 18 investment banks and brokerage houses. Instead of following the herd, their targets were unusual for their range, with some anticipating a further decline for stocks, but others forecasting a powerful rally. The average for the group pegged the S&P 500 at 4,031 by year's end.

See:Wall Street expects S&P 500 to finish 2023 at 4,000 after missing mark by the widest margin since 2008

The S&P 500 finished Thursday's session above that level at 4,160, its highest close since Aug. 25, according to FactSet data.

Several factors have played into its rebound since the beginning of the year.

'The January effect'

There are a few different theories about what's driving the latest hot streak in U.S. stocks. One is the January effect.

While stocks bottomed in October, the main indexes struggled to sustain their upward momentum in November and December. Although the S&P 500 barely eked out a Santa Claus Rally, the index finished the year down 19.4%, and many expected stocks to continue their downward trajectory in the first quarter of 2023.

So far, that hasn't happened. Instead, stocks broke out of a rangebound funk and moved higher shortly after the new year arrived. Fundamentally, not much had changed for the market, except for the calendar, said Steve Sosnick, chief strategist at Interactive Brokers.

"I think we've underestimated the January effect as an explanatory factor in what we've seen this month," Sosnick said.

Many of last year's worst performers helped to lead the rebound, another sign that seasonal capital flows were at least helping to bolster the rally, Sosnick said.

Some examples include Tesla Inc. (TSLA), which was the second-best S&P 500 stock in January after falling roughly 65% last year, and Carvana (CVNA), a troubled purveyor of cars that at one time had aspirations of being "the Amazon of used cars." Then there's also the ARK Innovation ETF(ARKK), which just notched its best month ever with a 27.8% gain in January.

'Goldilocks'

As economists and market strategists like to point out, nothing substantial has changed about the fundamentals of the U.S. economy over the past few months. Still, investors are feeling more sanguine about the possibility that the U.S. economy may avoid a punishing recession as inflation dissipates.

This notion has a name: "Goldilocks." Investors might be acting as if the U.S. economy will soon achieve this fairy-tale ideal, once again

"Investors are increasingly pricing in a benign, even a Goldilocks, mix of peak inflation/rates, a shallow recession, a boost to global demand from China reopening, the dissipation of energy supply concerns, and lower volatility overall," said Stephen Innes, managing partner at SPI Asset Management.

In a Thursday research note, a team of strategists from ING defined the current Goldilocks scenario as one "where inflation can come down, but unemployment does not have to rise."

Charlie McElligott, a cross-asset equity derivatives strategist at Nomura, defined it as "disinflation, but still resilient growth."

It isn't completely unjustified. The consumer-price index shows inflation has been waning for six months since peaking at its highest level in 41 years over the summer.

Data also show the U.S. labor market is still robust despite the Fed's most aggressive interest-rate hikes since the 1980s. Economists polled by The Wall Street Journal expect this trend to have continue in December data, forecasting 187,000 new jobs were created, compared with 223,000 the month before. The number of Americans applying for unemployment benefits has dropped to a 9-month low.

Still, the Fed signaled on Wednesday that it's planning more interest rate hikes, while Fed Chair Jerome Powell said he doesn't expect to cut interest rates before the end of the year, something that the market has been hoping for.

Some strategists expect stocks could swoon if the Fed ultimately disappoints.

"The worst of the monetary headwinds are behind us," Sosnick said about the Fed's rate hikes. "It doesn't mean the monetary headwinds have ended yet."

U.S. stocks added to their yearly gains on Thursday, with the S&P 500 achieving its first "golden cross" in two-and-a-half years. The large-cap index gained 1.5% to roughly 4,179, while the Nasdaq Composite rose 3.3% to about 12,200. The Dow Jones Industrial Average was the sole laggard of the major indexes, falling 0.1% to 34,053.

-Joseph Adinolfi

	

(END) Dow Jones Newswires

February 02, 2023 17:09 ET (22:09 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.